We help you join the dots...

RAS LSS is a niche strategy consultancy serving the global life sciences sector

 
 

Starting with Information Services in 2014, RAS LSS has evolved into a boutique healthcare consulting group. We offer a niche portfolio of Strategy Support and Information Services to Pharmaceutical and Medical Device Companies, throughout the product life-cycle.

We elucidate and contextualize current and future market complexities. Leveraging our collective intelligence, we strive to help our clients succeed via

  • Best In Class Situation Analysis
  • Competitively Differentiated Strategy
With an outreach across mature and emerging markets, we go the extra mile to create fresh perspectives for our clients in their mission to reduce the global burden of disease.

Check out our latest insights on rare diseses

We have put in the hours and the sweat to be credible…


Latest Blogs

June 2, 2018
Gastrointestinal cancer - ASCO18

Top ASCO 2018 Abstracts To Watch Out For In Gastrointestinal Cancers

Abstract 4011: A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal junction cancer refractory to trastuzumab (Herceptin) combined with fluoropyrimidine and platinum: WJOG7112G. Conclusion: Continuation of trastuzumab beyond progression (TMB Strategy) in this patient population was not found to have the […]
June 2, 2018
Breast cancer - ASCO18

Top ASCO 2018 Abstracts To Watch Out For In Breast Cancer

Abstract 506: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Conclusion: Trastuzumab’s known side effects include a risk for heart problems. The women who had […]
April 26, 2018
oxford_global

5th Biennial Biosimilars & Biobetters Congress, London

Last week London had a pretty good weather, slightly chilly evenings and surprisingly, sun-kissed mornings! Yes, we were there to attend the 5th Biennial Biosimilars & Biobetters Congress in London (since the event was in London. I guess it’s a mandate to start with a weather update J) It was […]
September 11, 2017
Targetted therapy

Anti-PD1 and PD-L1 Agents in Development

Distribution of Anti Pd-1 / Anti PD-L1 by Phase Related Post Major Milestones In Cancer Research Top ASCO 2018 Abstracts To Watch Out For In Lymphoma Top ASCO 2018 Abstracts To Watch Out For In Gastrointestinal Cancers
July 17, 2017
clinical_dev_biosimilar

Ongoing Biosimilar Clinical Development in Oncology

As the regulatory frameworks for biosimilar development are evolving in both US and EU, more and more biosimilar developers are entering the competitive landscape. Many commercially successful Oncology biologics are going off-patent in next few years, presenting a lucrative opportunity for biosimilar development. The biosimilars pertaining to these biologics constitute […]
June 19, 2017
Biosimilar dev in US and EU

Biosimilar Regulatory Development in US and EU

As per the 2015 IMS report, the global biologics market is projected to reach 28% of the global pharmaceuticals market by 2020 [1]. This would translate to the biologics market potentially worth USD 390 billion in 2020. As many of the biologics will face patent expiration in the next 5 […]